ImmunityBio (IBRX) Common Equity (2013 - 2026)
ImmunityBio (IBRX) reported Common Equity of -$869.1 million for Q1 2026, down 47.19% year-over-year from -$1.6 billion in Q1 2025, and down 73.97% quarter-over-quarter from -$499.6 million in Q4 2025.
ImmunityBio (IBRX) Common Equity (2013 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 14 years of Common Equity data on file, last reported at -$869.1 million in Q1 2026.
- Common Equity for Q1 2026 came in at -$869.1 million, down 47.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$869.1 million (down 47.19% YoY), and the FY2025 annual result was -$499.6 million, down 2.34% from the prior year.
- Common Equity declined to -$869.1 million in Q1 2026 per IBRX's latest filing, from -$499.6 million in the prior quarter.
- Over five years, Common Equity peaked at -$337.6 million in Q1 2022 and troughed at -$869.1 million in Q1 2026.
- A 5-year average of -$557.9 million and a median of -$531.7 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 166.09% in 2022, then rose 29.66% in 2025.
- A 5-year view of Common Equity shows it stood at -$449.8 million in 2022, then plunged by 30.26% to -$585.9 million in 2023, then grew by 16.69% to -$488.1 million in 2024, then slipped by 2.34% to -$499.6 million in 2025, then plunged by 73.97% to -$869.1 million in 2026.
- Business Quant data shows IBRX's Common Equity at -$869.1 million in Q1 2026, -$499.6 million in Q4 2025, and -$523.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -869.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -869.13 Mn |
| Dec 31, 2025 | -499.57 Mn |
| Sep 30, 2025 | -523.41 Mn |
| Jun 30, 2025 | -569.82 Mn |
| Mar 31, 2025 | -590.48 Mn |
| Dec 31, 2024 | -488.13 Mn |
| Sep 30, 2024 | -744.16 Mn |
| Jun 30, 2024 | -697.38 Mn |
| Mar 31, 2024 | -690.98 Mn |
| Dec 31, 2023 | -585.94 Mn |
| Sep 30, 2023 | -410.65 Mn |
| Jun 30, 2023 | -645.18 Mn |
| Mar 31, 2023 | -531.72 Mn |
| Dec 31, 2022 | -449.82 Mn |
| Sep 30, 2022 | -429.08 Mn |
| Jun 30, 2022 | -421.97 Mn |
| Mar 31, 2022 | -337.56 Mn |
| Dec 31, 2021 | -243.91 Mn |
| Sep 30, 2021 | -189.94 Mn |
| Jun 30, 2021 | -158.59 Mn |